AI Article Synopsis
- Liver metastases occur in about 20.3% of kidney cancer patients, and this study aimed to evaluate how effective surgical treatment is for these metastases.
- A thorough literature search found 935 potential studies, but only 13 met the criteria for this systematic review, revealing a wide range of survival rates after surgery.
- The findings suggest that while surgery is only performed in around 1% of liver metastasis cases, it may offer a potentially curative option for carefully selected patients with metastatic kidney cancer.
Article Abstract
Background: Liver metastases are present in 20.3% of metastatic kidney cancers. The aim of this literature review was to assess the efficacy of surgical treatment for hepatic metastasis from kidney cancer.
Methods: An extended web search of the literature was independently performed in March 2018 by two authors according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement.
Results: Through electronic searches, we identified 935 potentially relevant citations. Thirteen articles were finally included in the systematic review. Median survival after resection ranged from 15 to 142 months while the 1-, 3- and 5-year overall survival ranged from 69% to 100%, 26% to 83.3% and 0% to 62%, respectively. Median disease-free survival ranged from 7.2 to 27 months.
Conclusion: Surgical treatment of hepatic metastases is performed in approximately 1% of patients with liver metastases and in select patients may be potentially curative. Surgical resection of liver metastases from kidney cancer represents a valid option for selected patients with metastatic renal cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ans.15000 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!